Compound: 154447-36-6
SMILES: O=c1c2c(oc(c1)N3CCOCC3)c(-c4ccccc4)ccc2
InChIKey: CZQHHVNHHHRRDU-UHFFFAOYSA-N
Synonyms: 154447-36-6, LY294002, LY 294002, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, LY-294002, 2-morpholin-4-yl-8-phenylchromen-4-one, 31M2U1DVID, NSC-697286, SF-1101, DTXSID6042650, 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-, CHEBI:65329, RefChem:458194, DTXCID4022650, PI3K/BET INHIBITOR LY294002, 2-morpholino-8-phenyl-4H-chromen-4-one, 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one, MFCD00270881, 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one, 15447-36-6, 2-morpholino-8-phenyl-chromen-4-one, NSC 697286, 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE, CHEMBL98350, LY2, LY-294,002, UNII-31M2U1DVID, BMK1-D5, 2-Morpholino-8-phenylchromone, Lys 294002, 4azt, Kinome_3543, Tocris-1130, 1yi3, BiomolKI_000029, 2-(morpholin-4-yl)-8-phenylchromen-4-one, Lopac-L-9908, 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one, BiomolKI2_000037, CBiol_002046, Lopac0_000710, SCHEMBL94377, BSPBio_001223, KBioGR_000563, KBioSS_000563, MLS006010131, 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl, GTPL6004, orb1306761, SCHEMBL29424167, BCBcMAP01_000117, BDBM12915, KBio2_000563, KBio2_003131, KBio2_005699, KBio3_001005, KBio3_001006, EX-A073, Bio1_000332, Bio1_000821, Bio1_001310, Bio2_000442, Bio2_000922, HMS1362M05, HMS1792M05, HMS1990M05, HMS3229G17, HMS3403M05, HMS3649E04, HMS3654M21, EBC-11275, HSCI1_000206, NSC697286, NSC755769, s1105, AKOS017344742, CCG-100633, CS-0150, DB02656, FM34126, NSC-755769, SB10965, SDCCGSBI-0050688.P003, SDCCGSBI-0050688.P009, SF 1101, IDI1_002197, NCGC00015622-01, NCGC00015622-02, NCGC00015622-03, NCGC00015622-04, NCGC00015622-05, NCGC00015622-06, NCGC00015622-07, NCGC00015622-23, NCGC00015622-27, NCGC00025020-01, NCGC00025020-02, NCGC00025020-03, NCGC00025020-04, NCGC00179253-01, AC-30295, AS-16252, HY-10108, NCI60_034712, SMR002530642, SY052711, 2-Morpholin-4-yl-8-phenyl-chromen-4-one, DB-228223, LY-924002, LY294002?, M2410, NS00068117, SW217688-2, 2-(4-Morpholinyl)-8-phenyl-4H-chromen-4-one, 2-Morpholino-8-phenyl-4-oxo-4H-1-benzopyran, K00235, EN300-1692893, Q4042503, SR-01000076245-7, 2-(Morpholin-4-yl)-8-phenyl-4H-1-benzopyran-4-one, BRD-K27305650-001-05-9, BRD-K27305650-001-16-6, BRD-K27305650-003-02-2, LY-294,002 hydrochloride, solid, >=98% (HPLC), Z211317670, LY 294002 - CAS 154447-36-6, 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI), H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI), LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one
Theoretical properties:
molecular_formula: C19H17NO3
molecular_weight: 307.3 g/mol
exact_mass: 307.12084340 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 2
heavy_atom_count: 23
topological_polar_surface_area: 38.8 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: LY294002 is a chromone substituted with a phenyl group at position 8 and a morpholine group at position 2. It has a role as a geroprotector, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an autophagy inhibitor. It is a member of chromones, an organochlorine compound and a member of morpholines.
chebi: A chromone substituted with a phenyl group at position 8 and a morpholine group at position 2.
chembl: LY-294002 is a small molecule listed in the ChEMBL database and has reached clinical trial phase -1.0.
wikipedia: LY294002 is a morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks). It is generally considered a non-selective research tool, and should not be used for experiments aiming to target PI3K uniquely.
Two of these are the proto-oncogene serine/threonine-protein kinase (PIM1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase P110 gamma|catalytic subunit gamma isoform.  With an IC50 of 1.4 μM it is somewhat less potent than wortmannin, another well-known PI3 kinase inhibitor. However, LY294002 is a reversible inhibitor of PI3K whereas wortmannin acts irreversibly.
Application of LY294002 causes a substantial acceleration of MEPP frequency (150 μM) at the frog neuromuscular junction through a mechanism that is independent of intraterminal calcium. LY294002 causes the release of MEPPs through a perturbation of synaptotagmin function.
LY294002 is also a BET inhibitor (e.g. of BRD2, BRD3, and BRD4).